Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of daxdilimab in dermatomyositis or anti-synthetase inflammatory myositis
ISRCTN44828082Phase 2Completed
- Sponsor
- Horizon Therapeutics
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in dermatomyositis (DM) and antisynthetase syndrome (ASSD) comparing Daxdilimab with Placebo to daxdilimab (2 arms). Primary endpoint: Total improvement score at Week 24. Started Oct 2023; status: completed.
02
Drugs
daxdilimab
03
Conditions
dermatomyositis (DM)antisynthetase syndrome (ASSD)
Beyond the preview
Go deeper on ISRCTN44828082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN44828082.